As we move into the next year of our work, RCRF is laser-focused on eliminating the inequities of rare cancer through a patient-driven approach that accelerates discovery, collaboration, and the development of treatments for every patient. This is a pivotal moment for our organization and it is our time to maximize impact.
Over the past decade, RCRF has built a powerful and essential research infrastructure, delivering measurable results and challenging the long-standing scarcity of resources dedicated to rare cancer research. In 2026, our North Star is clear: to enhance, strengthen, and accelerate our nonprofit so we can broaden and deepen our impact.
We will continue to serve researchers, scientists, hospital systems, academic institutions, biostatisticians, and physicians—always with the patient at the center—by expanding tissue collection and biobanking, strengthening data infrastructure and harmonization of clinical and molecular data, and leading additional coordinated research efforts.
RCRF will further amplify our role as a central hub for collaboration, harnessing collective expertise to maximize impact and empower patients to drive meaningful scientific progress. Through this 2026 growth strategy, we will continue to fight for cures for rare cancers—driven by patients, achieved through research.
We ask you to join us as we move forward in breaking down barriers and advancing innovative strategies to make 2026 a defining year of impact.
